Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Neurogene (NGNE) Return on Sales (2018 - 2025)

Neurogene's Return on Sales history spans 6 years, with the latest figure at 1149.72% for Q4 2025.

  • For Q4 2025, Return on Sales rose 123059.0% year-over-year to 1149.72%; the TTM value through Dec 2025 reached 1149.72%, up 123059.0%, while the annual FY2024 figure was 81.84%, N/A changed from the prior year.
  • Return on Sales reached 1149.72% in Q4 2025 per NGNE's latest filing, up from 1084.71% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 17547.67% in Q4 2023 to a low of 80.87% in Q4 2024.
  • Average Return on Sales over 3 years is 4686.12%, with a median of 1117.22% recorded in 2025.
  • The largest YoY upside for Return on Sales was 140033bps in 2024 against a maximum downside of -1762854bps in 2024.
  • A 3-year view of Return on Sales shows it stood at 17547.67% in 2023, then plummeted by -100bps to 80.87% in 2024, then surged by 1522bps to 1149.72% in 2025.
  • Per Business Quant, the three most recent readings for NGNE's Return on Sales are 1149.72% (Q4 2025), 1084.71% (Q3 2025), and 1075.21% (Q2 2025).